Arcturus Therapeutics to Present at Leerink’s Global Healthcare Conference 2025

Rhea-AI Summary

Arcturus Therapeutics (Nasdaq: ARCT), a commercial messenger RNA medicines company specializing in infectious disease vaccines and liver and respiratory rare diseases, has announced its participation in Leerink's Global Healthcare Conference 2025. The company will engage in a fireside chat session scheduled for Wednesday, March 12, 2025, at 10:40 a.m. Eastern Time in Miami. Interested parties can access the webcast through the Investor Relations/Events section of the Arcturus website.

SAN DIEGO--(BUSINESS WIRE)-- Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases, today announced that the Company will participate at a fireside chat hosted by Leerink’s Global Healthcare Conference 2025 in Miami, on Wednesday, March 12, 2025, at 10:40 a.m. Eastern Time.

Webcast link can be found under Investor Relations/Events section of Arcturus’ website.

About Arcturus

Founded in 2013 and based in San Diego, California, Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT) is a commercial mRNA medicines and vaccines company with enabling technologies: (i) LUNAR® lipid-mediated delivery, (ii) STARR® mRNA technology (sa-mRNA) and (iii) mRNA drug substance along with drug product manufacturing expertise. Arcturus developed KOSTAIVE®, the first self-amplifying messenger RNA (sa-mRNA) COVID vaccine in the world to be approved. Arcturus has an ongoing global collaboration for innovative mRNA vaccines with CSL Seqirus, and a joint venture in Japan, ARCALIS, focused on the manufacture of mRNA vaccines and therapeutics. Arcturus’ pipeline includes RNA therapeutic candidates to potentially treat ornithine transcarbamylase (OTC) deficiency and cystic fibrosis (CF), along with its partnered mRNA vaccine programs for SARS-CoV-2 (COVID-19) and influenza. Arcturus’ versatile RNA therapeutics platforms can be applied toward multiple types of nucleic acid medicines including messenger RNA, small interfering RNA, circular RNA, antisense RNA, self-amplifying RNA, DNA, and gene editing therapeutics. Arcturus' technologies are covered by its extensive patent portfolio (over 500 patents and patent applications in the U.S., Europe, Japan, China, and other countries). For more information, visit www.ArcturusRx.com. In addition, please connect with us on Twitter and LinkedIn.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250305926701/en/

Arcturus Therapeutics

Public Relations & Investor Relations

Neda Safarzadeh

VP, Head of IR/PR/Marketing

(858) 900-2682

IR@ArcturusRx.com

Source: Arcturus Therapeutics Holdings Inc.

FAQ

When is Arcturus Therapeutics (ARCT) presenting at Leerink's Global Healthcare Conference 2025?

Arcturus Therapeutics will present on Wednesday, March 12, 2025, at 10:40 a.m. Eastern Time in Miami.

How can investors watch Arcturus Therapeutics' (ARCT) presentation at Leerink's Conference?

Investors can access the webcast through the Investor Relations/Events section of Arcturus' website.

What type of presentation will ARCT deliver at Leerink's Global Healthcare Conference 2025?

Arcturus will participate in a fireside chat format presentation at the conference.

What is Arcturus Therapeutics' (ARCT) main business focus?

Arcturus is a commercial messenger RNA medicines company focused on developing infectious disease vaccines and treatments for liver and respiratory rare diseases.